Author
Listed:
- Matthew W. Fittall
(The Francis Crick Institute
University College London Cancer Institute
Wellcome Trust Sanger Institute)
- William Mifsud
(University College London Cancer Institute
Wellcome Trust Sanger Institute
Great Ormond Street Hospital for Children NHS Foundation Trust)
- Nischalan Pillay
(University College London Cancer Institute
Royal National Orthopaedic Hospital NHS Trust)
- Hongtao Ye
(Royal National Orthopaedic Hospital NHS Trust)
- Anna-Christina Strobl
(Royal National Orthopaedic Hospital NHS Trust)
- Annelien Verfaillie
(The Francis Crick Institute)
- Jonas Demeulemeester
(The Francis Crick Institute
University of Leuven)
- Lei Zhang
(Memorial Sloan Kettering Cancer Center)
- Fitim Berisha
(Royal National Orthopaedic Hospital NHS Trust)
- Maxime Tarabichi
(The Francis Crick Institute
Wellcome Trust Sanger Institute)
- Matthew D. Young
(Wellcome Trust Sanger Institute)
- Elena Miranda
(University College London Cancer Institute)
- Patrick S. Tarpey
(Wellcome Trust Sanger Institute)
- Roberto Tirabosco
(Royal National Orthopaedic Hospital NHS Trust)
- Fernanda Amary
(Royal National Orthopaedic Hospital NHS Trust)
- Agamemnon E. Grigoriadis
(Guy’s Hospital)
- Michael R. Stratton
(Wellcome Trust Sanger Institute)
- Peter Loo
(The Francis Crick Institute
University of Leuven)
- Cristina R. Antonescu
(Memorial Sloan Kettering Cancer Center)
- Peter J. Campbell
(Wellcome Trust Sanger Institute)
- Adrienne M. Flanagan
(University College London Cancer Institute
Royal National Orthopaedic Hospital NHS Trust)
- Sam Behjati
(Wellcome Trust Sanger Institute
University of Cambridge)
Abstract
The transcription factor FOS has long been implicated in the pathogenesis of bone tumours, following the discovery that the viral homologue, v-fos, caused osteosarcoma in laboratory mice. However, mutations of FOS have not been found in human bone-forming tumours. Here, we report recurrent rearrangement of FOS and its paralogue, FOSB, in the most common benign tumours of bone, osteoblastoma and osteoid osteoma. Combining whole-genome DNA and RNA sequences, we find rearrangement of FOS in five tumours and of FOSB in one tumour. Extending our findings into a cohort of 55 cases, using FISH and immunohistochemistry, provide evidence of ubiquitous mutation of FOS or FOSB in osteoblastoma and osteoid osteoma. Overall, our findings reveal a human bone tumour defined by mutations of FOS and FOSB.
Suggested Citation
Matthew W. Fittall & William Mifsud & Nischalan Pillay & Hongtao Ye & Anna-Christina Strobl & Annelien Verfaillie & Jonas Demeulemeester & Lei Zhang & Fitim Berisha & Maxime Tarabichi & Matthew D. You, 2018.
"Recurrent rearrangements of FOS and FOSB define osteoblastoma,"
Nature Communications, Nature, vol. 9(1), pages 1-6, December.
Handle:
RePEc:nat:natcom:v:9:y:2018:i:1:d:10.1038_s41467-018-04530-z
DOI: 10.1038/s41467-018-04530-z
Download full text from publisher
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:9:y:2018:i:1:d:10.1038_s41467-018-04530-z. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.